Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31621192 | 0.79 | THRA (0.39) | RXRAPPARGCYP3A4 | |
| SCHEMBL28634307 | 0.78 | ALDH1A1 (0.49) | VCAM1TSHRFFAR4FFAR1 | |
| SCHEMBL20982803 | 0.78 | HRH3 (0.41) | CYP3A4 | |
| SCHEMBL20475470 | 0.77 | TSHR (0.40) | TSHRFFAR4FFAR1RXRAPPARG | |
| SCHEMBL7164671 | 0.76 | TSHR (0.45) | TSHRFFAR4FFAR1PPARGCYP3A4 | |
| Elsibucol SCHEMBL6002307 | 0.75 | VCAM1 (0.73) | VCAM1GPR55 | |
| SCHEMBL13449878 | 0.75 | VCAM1 (0.59) | VCAM1TSHRFFAR4FFAR1 | |
| SCHEMBL5984227 | 0.73 | GABBR2 (0.34) | TSHRGPR55CYP3A4 | |
| SCHEMBL7568496 | 0.72 | TUBB1 (0.51) | TSHRFFAR4PPARA | |
| SCHEMBL8347943 | 0.72 | VCAM1 (0.56) | VCAM1TSHRGPR55FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527788-B2 | Defining RNA-small molecule affinity landscapes enables design of a small molecule inhibitor of an oncogenic non-coding RNA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240293398-A1 | Defining RNA-Small Molecule Affinity Landscapes Enables Design of a Small Molecule Inhibitor... | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-09-05 | — | — | US | disclosed |
| WO-2018151810-A1 | DEFINING RNA-SMALL MOLECULE AFFINITY LANDSCAPES ENABLES DESIGN OF A SMALL MOLECULAR INHIBITOR OF AN ONCOGENIC NON-CODING RNA | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527788-B2 | Defining RNA-small molecule affinity landscapes enables design of a small molecule inhibitor of an oncogenic non-coding RNA | STUB1, TARBP1, STK16 | VCAM1 3159/4885TSHR 1439/4885GPR55 4565/4885 |
| US-20240293398-A1 | Defining RNA-Small Molecule Affinity Landscapes Enables Design of a Small Molecule Inhibitor... | TARBP1, STK16, STK38 | VCAM1 2996/4885TSHR 1639/4885GPR55 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.